This special supplement to Diagnostic Imaging and Oncology News International focuses on selected reports about CT, MRI, and PET from the 2004 meetings of the Radiological Society of North America and the American Society for Therapeutic Radiology and Oncology.
This special supplement to Diagnostic Imaging and Oncology News International focuses on selected reports about CT, MRI, and PET from the 2004 meetings of the Radiological Society of North America and the American Society for Therapeutic Radiology and Oncology.
Expert commentary puts these techniques into the context of daily practice in clinical oncology. Discussion shows the significant ways in which MRI, CT, and PET have evolved in recent years and how they complement each other, not only in diagnosis but also in staging tumors and targeting treatments such as focused ultrasound, ablation, and chemotherapy.
-Jane Lowers
Special Projects Editor
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.